Bruce Keyt

Dr. Keyt has served as the Chief Scientific Officer since 2012, after serving in that role as a consultant beginning in 2010. Prior to joining IGM, Dr. Keyt served as Chief Technology Officer at Trellis Bioscience, an antibody discovery company, from 2007 to 2010. Previously, he served as Head of Research for Abmaxis, a biotechnology company, from 2005 through its acquisition by Merck in 2006. He was also Vice President of Preclinical Development at Abgenix, a biotechnology company, from 2001 through its acquisition by Amgen in 2005. Dr. Keyt was the Director of Pharmacology at Millennium Pharmaceuticals from 1998 to 2001. From 1982 to 1998, he served in various research and leadership roles at Roche/Genentech, where he made significant contributions to the discovery and development of Avastin, Lucentis, Activase tPA, TNKase-tPA and Kogenate (Factor VIII). Dr. Keyt received a B.A. in Chemistry from Washington University in St. Louis and a Ph.D. in Biochemistry and Pharmacology from Tufts University School of Medicine.